Pece Alfredo, Allegrini Davide, Montesano Giovanni, Dimastrogiovanni Andrea Fabio
Eye Clinic, Melegnano Hospital, Vizzolo Predabissi, Italy.
Eye Clinic, San Paolo Hospital, Università di Milano, Milano, Italy.
Clin Ophthalmol. 2016 Jun 17;10:1131-8. doi: 10.2147/OPTH.S106096. eCollection 2016.
The purpose of this study is to make a prospective evaluation of the effect of timolol 0.1% eye gel on short-term intraocular pressure (IOP) after an intravitreal injection (IVI) of ranibizumab.
One hundred and fifty eyes of 150 IVI-naïve patients with macular edema caused by various pathological conditions (age-related macular degeneration, central or branch retinal vein occlusion, and diabetic retinopathy) were scheduled to undergo an IVI of ranibizumab (0.5 mg/0.05 cc). The patients were randomly divided into three groups: 50 were not treated with timolol before the IVI (group 1); 50 received an instillation of timolol 0.1% eye gel the evening before the IVI (group 2); and 50 received an instillation of timolol 0.1% eye gel 2 hours before the IVI (group 3). The incidence of clinically significant intraocular hypertensive spikes (>25 mmHg and >40 mmHg) was then assessed.
Our findings showed that mean IOP at baseline was significantly higher than at both 5 and 60 minutes after IVI (P<0.01). Spikes of >25 mmHg were recorded at either time in 27 patients (54%) in group 1, 23 patients (44%) in group 2, and 24 patients (48%) in group 3. None of the between-group differences were significant. Spikes of >40 mmHg (which were only detected 5 minutes after IVI) were recorded in nine (18%), eight (16%), and one patient (2%) in groups 1, 2, and 3, respectively. The only significant difference was between the control and group 3 (P=0.012).
An increase in IOP after antivascular endothelial growth factor IVI is a frequent complication. The prophylactic use of timolol 0.1% gel effectively reduced the mean IOP when administered 2 hours before IVI and was also effective in preventing dangerous IOP spikes of >40 mmHg. It is therefore recommended before IVIs as a means of preventing emergency procedures and preserving the health of the optic nerve.
本研究旨在对0.1%噻吗洛尔眼凝胶在玻璃体内注射(IVI)雷珠单抗后对短期眼压(IOP)的影响进行前瞻性评估。
150例初诊的因各种病理状况(年龄相关性黄斑变性、视网膜中央或分支静脉阻塞以及糖尿病性视网膜病变)导致黄斑水肿的患者的150只眼计划接受雷珠单抗(0.5mg/0.05cc)玻璃体内注射。患者被随机分为三组:50例在玻璃体内注射前未用噻吗洛尔治疗(第1组);50例在玻璃体内注射前一晚滴注0.1%噻吗洛尔眼凝胶(第2组);50例在玻璃体内注射前2小时滴注0.1%噻吗洛尔眼凝胶(第3组)。然后评估临床上显著的高眼压峰值(>25mmHg和>40mmHg)的发生率。
我们的研究结果表明,基线时的平均眼压显著高于玻璃体内注射后5分钟和60分钟时的眼压(P<0.01)。第1组27例患者(54%)、第2组23例患者(44%)和第3组24例患者(48%)在两个时间点均记录到>25mmHg的眼压峰值。组间差异均无统计学意义。>40mmHg的眼压峰值(仅在玻璃体内注射后5分钟检测到)在第1组、第2组和第3组中分别有9例(18%)、8例(16%)和1例患者(2%)记录到。唯一显著的差异是对照组与第3组之间(P=0.012)。
抗血管内皮生长因子玻璃体内注射后眼压升高是一种常见并发症。在玻璃体内注射前2小时给予0.1%噻吗洛尔凝胶预防性使用可有效降低平均眼压,并且在预防>40mmHg的危险眼压峰值方面也有效。因此,建议在玻璃体内注射前使用,作为预防紧急手术和保护视神经健康的一种手段。